This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Moxaverine
- DrugBank Accession Number
- DB12251
- Background
Moxaverine has been investigated for the treatment of Retina, Ocular Physiology, and Regional Blood Flow.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
Structure for Moxaverine (DB12251)
- Weight
- Average: 307.393
Monoisotopic: 307.15722892 - Chemical Formula
- C20H21NO2
- Synonyms
- Moxaverine
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Moxaverine Hydrochloride 6R0I0E99CN 1163-37-7 DULZSDGCXSLVAQ-UHFFFAOYSA-N
Categories
- ATC Codes
- A03AD30 — Moxaverine
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as benzylisoquinolines. These are organic compounds containing an isoquinoline to which a benzyl group is attached.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Isoquinolines and derivatives
- Sub Class
- Benzylisoquinolines
- Direct Parent
- Benzylisoquinolines
- Alternative Parents
- Anisoles / Alkyl aryl ethers / Pyridines and derivatives / Benzene and substituted derivatives / Heteroaromatic compounds / Azacyclic compounds / Organopnictogen compounds / Organonitrogen compounds / Hydrocarbon derivatives
- Substituents
- Alkyl aryl ether / Anisole / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Benzylisoquinoline / Ether / Heteroaromatic compound / Hydrocarbon derivative / Monocyclic benzene moiety
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- P3P08Y1XJ4
- CAS number
- 10539-19-2
- InChI Key
- MYCMTMIGRXJNSO-UHFFFAOYSA-N
- InChI
- InChI=1S/C20H21NO2/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14/h5-9,11-13H,4,10H2,1-3H3
- IUPAC Name
- 1-benzyl-3-ethyl-6,7-dimethoxyisoquinoline
- SMILES
- CCC1=NC(CC2=CC=CC=C2)=C2C=C(OC)C(OC)=CC2=C1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 70882
- PubChem Substance
- 347828526
- ChemSpider
- 64045
- 52918
- ChEBI
- 135307
- ChEMBL
- CHEMBL2105060
- ZINC
- ZINC000000001754
- Wikipedia
- Moxaverine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Basic Science Effect of Orally Administrated Moxaverine on Ocular Blood Flow 1 2 Completed Treatment Ischaemia 1 2 Completed Treatment Physiology, Ocular / Regional Blood Flow / Retina 1 2, 3 Completed Treatment Glaucoma / Macular Degeneration / Regional Blood Flow 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00102 mg/mL ALOGPS logP 5.01 ALOGPS logP 4.23 Chemaxon logS -5.5 ALOGPS pKa (Strongest Basic) 6.49 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 31.35 Å2 Chemaxon Rotatable Bond Count 5 Chemaxon Refractivity 91.81 m3·mol-1 Chemaxon Polarizability 35.02 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 21:43 / Updated at February 21, 2021 18:53